Soleno Therapeutics(SLNO) - 2023 Q4 - Annual Report
Soleno Therapeutics(SLNO)2024-03-07 09:03
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 77-0523891 (State or other Jurisdiction ...